Last updated: March 22, 2022. Click here to view log of changes to our data and website.
Corticosteroids, interleukin-6 inhibitors receptor antagonists, and janus kinase inhibitors probably reduce mortality and confer other important benefits in patients with severe covid-19. Molnupiravir probably reduces admission to hospital in patients with non-severe covid-19.
Hydroxychloroquine prophylaxis has trivial to no eﬀect on hospital admission and mortality, probably increases adverse eﬀects, and probably does not reduce the risk of SARS-CoV-2 infection. Because of serious risk of bias and very serious imprecision, it is highly uncertain whether ivermectin combined with iota-carrageenan and ivermectin alone reduce the risk of SARS-CoV-2 infection.
There is no clear eﬀect of bamlanivimab, convalescent plasma, or IVIG on patient- important outcomes. Properly evaluating the safety and eﬃcacy of humoral and cellular therapies for the treatment of covid-19 will requires data from additional large randomised trials.